Crossmark

ASO Visual Abstract: Neoadjuvant Chemotherapy Does Not Improve Survival in cT2N0M0 Gastric Adenocarcinoma Patients—A Multicenter Propensity Score Analysis

Crossref DOI link: https://doi.org/10.1245/s10434-024-15533-0

Published Online: 2024-07-27

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abboretti, Francesco

Lambert, Céline

Schäfer, Markus

Pereira, Bruno

Le Roy, Bertrand

Mège, Diane

Piessen, Guillaume

Gagnière, Johan

Gronnier, Caroline

Mantziari, Styliani https://orcid.org/0000-0003-1315-1898
,

,
License Information

Text and Data Mining valid from 2024-07-27

Version of Record valid from 2024-07-27
More Information

Article History

First Online: 27 July 2024

Disclosures

: Dr. Guillaume Piessen. BMS: consulting, board. Nestlé: consulting. Astellas pharma: consulting. Medtronic: travel, accommodation. MSD: travel, accommodation, consulting. Daiichi: consulting.

Document is current

Any future updates will be listed below